Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Contributed by: ACCESSWIRE

Logo

Tags

Healthcare & Pharmaceutical

Moderna, Inc.

NASDAQ:MRNA

Product Announcements

More Like This

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)

PR Newswire associated0

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

CEPI y Moderna aprovechan la tecnología ARNm para avanzar en la Misión de los 100 días